DNLI
Denali Therapeutics Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom -4.1% · netto nieuwe posities 0.0% — formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 97 | +6 | 103.66M | $2.65B | +11 | −4 |
| Q1 2026 | 93 | +4 | 96.77M | $1.85B | +11 | −8 |
| Q4 2025 | 89 | 0 | 110.68M | $1.83B | +1 | — |
| Q3 2025 | 19 | 0 | 67.26M | $976.61M | — | −1 |
| Q2 2025 | 17 | +1 | 74.76M | $1.05B | +2 | −1 |
| Q1 2025 | 13 | +1 | 44.98M | $611.55M | +2 | −1 |
| Q4 2024 | 12 | -1 | 38.31M | $780.78M | — | −1 |
| Q3 2024 | 12 | 0 | 34.10M | $993.27M | +1 | −1 |
| Q2 2024 | 12 | — | 35.56M | $825.78M | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 13.35M | -3.0% | $388.77M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 13.35M | -3.0% | $388.77M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 13.35M | -3.0% | $388.77M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 13.35M | -3.0% | $388.77M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 10.73M | +9.2% | $312.49M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 10.73M | +9.2% | $312.49M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 10.73M | +9.2% | $312.49M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 10.73M | +9.2% | $312.49M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 10.73M | +9.2% | $312.49M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 10.73M | +9.2% | $312.49M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 10.73M | +9.2% | $312.49M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passief) | 2.96M | -0.9% | $86.11M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Geode Capital Management ✦ (passief) | 2.96M | -0.9% | $86.11M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 2.87M | +27.2% | $83.60M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 2.87M | +27.2% | $83.60M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | Marshall Wace ✦ | 1.97M | -18.7% | $57.30M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 777.28K | -36.2% | $22.64M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 547.33K | +14.5% | $15.94M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 19 | Norges Bank ✦ (passief) | 397.54K | -51.8% | $11.58M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | Point72 Asset Management ✦ | 333.53K | -68.3% | $9.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 99.47K | +4.8% | $2.90M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 22 | Millennium Management ✦ | 60.17K | -90.3% | $1.75M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 16.02K | Nieuw | $466,605 | 0.0% | New | 1 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 16.02K | Nieuw | $466,605 | 0.0% | New | 1 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 16.02K | Nieuw | $466,605 | 0.0% | New | 1 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| AQR Capital Management | $466,605 | 0.0% |
| AQR Capital Management | $466,605 | 0.0% |
| AQR Capital Management | $466,605 | 0.0% |
Verlaten
| D. E. Shaw & Co. | $690,122 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 265 houders, 147.10M aandelen, $2.60B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 2.86K aand · $71,625
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie